TICKERNERD
Menu
HUMHUMHealthcare · Healthcare Plans

HUM Stock Forecast: Humana, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$417
−0.10% on the day

The 26 Wall Street analysts covering Humana, Inc. hold a median 12-month price target of $473 — +13.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 4 Nov 2026 — in the upper half.

Market cap
$49.3B
Ticker Nerd rank
51/ 100
Median analyst target
$473
Analysts covering
26
Revenue$40.9B+26.2% y/y
Net income$693.0M
Free cash flow$1.8B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.6%
1M
+7.7%
YTD
+64.5%
1Y
+50.0%
From 52W high
−3.5%
From 52W low
+157.5%
$162
$433
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HUM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Humana, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
51/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
90
Volatility
80
Value
69
Revisions
60
Growth
54
Issuance
53
Accruals
35
Quality
33
Size
5

Momentum (90): The shares have been drifting up relative to others.

Quality (33): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Size (5): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

HUM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HUM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$200$300$400$500$600Jan 26Apr 26Jul 26Oct 26HUMHigh $596Median $473Low $280

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says26 analysts
16 Buy9 Hold1 Sell
Low $280Median $473High $596

The green dot is the last close — the median target sits +13.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 13 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
13 Oct 2026MizuhoMaintainsOutperform$468 → $495
12 Oct 2026OppenheimerMaintainsOutperform$475 → $525
12 Oct 2026Raymond JamesUpgradeOutperform$520
12 Oct 2026Truist SecuritiesMaintainsHold$415 → $475
12 Oct 2026UBSMaintainsNeutral$405 → $495
9 Oct 2026BairdUpgradeOutperform$390 → $596
9 Oct 2026BarclaysMaintainsOverweight$515 → $582
9 Oct 2026OppenheimerMaintainsOutperform$405 → $475
7 Oct 2026Cantor FitzgeraldUpgradeOverweight$300 → $460
25 Sept 2026BarclaysUpgradeOverweight$407 → $515
25 Sept 2026BarclaysUpgradeOverweight—
10 Aug 2026JP MorganMaintainsNeutral$316 → $393
10 Aug 2026JP MorganMaintainsNeutral—
5 Aug 2026Morgan StanleyUpgradeEqual-Weight$249 → $370
5 Aug 2026Morgan StanleyUpgradeEqual-Weight—
31 July 2026BarclaysMaintainsEqual-Weight$344 → $407
31 July 2026BarclaysMaintainsEqual-Weight—
31 July 2026TD CowenMaintainsHold$350 → $370
31 July 2026TD CowenMaintainsHold—
30 July 2026Evercore ISI GroupUpgradeOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

HUM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

HUM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Humana, Inc. returned +50.0% against +14.8% for the S&P 500, dividends included.

HUM vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Jan 26Apr 26Jul 26Oct 26HUMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HUM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+2.3%
Analysts raising
5
Analysts cutting
1
Fundamentals

Humana, Inc. (HUM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
38.8×

Cheaper than 19% of US stocks

Price / sales
0.3×

Cheaper than 86% of US stocks

Price / book
2.6×

Cheaper than 35% of US stocks

EV / EBITDA
11.2×

Cheaper than 33% of US stocks

Growth & margins
Revenue growth (YoY)
26.2%

Higher than 75% of US stocks

Earnings growth (YoY)
27.3%

Higher than 65% of US stocks

Gross margin
—
Operating margin
3.5%

Higher than 51% of US stocks

Net margin
0.9%

Higher than 49% of US stocks

Returns & dividend
Return on equity
6.9%

Higher than 57% of US stocks

Return on assets
3.9%

Higher than 70% of US stocks

Dividend yield
0.9%

Higher than 69% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Humana, Inc. (HUM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Humana, Inc. has a market value of $49.3B and an enterprise value of $40.2B.

  • Revenue in the twelve months to 30 June 2026: $145.7B. The latest quarter grew 26.2% year on year.

  • Net income over the same four quarters: $1.3B, a 0.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: $1.9B.

  • Humana, Inc. spent $150.0M on share buybacks and $430.0M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 120.1M.

  • Trailing P/E: 38.8×; forward P/E: 24.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.86%, paying out 33% of earnings.

  • Humana, Inc. employs 67,060 people — $2.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Nov 2026

Data provided by Twelve Data

Peers

HUM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealthcare Plans
CompanyMarket capTKN rank
HUMHumana, Inc.$49.3B51
CNCCentene Corp.$37.4B93
CIThe Cigna Group$80.7B77
ELVElevance Health, Inc.$96.5B77
CVSCVS Health Corp.$101.5B79
MOHMolina Healthcare, Inc.$11.8B34
OSCROscar Health, Inc.$10.5B90

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Humana, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HUM news & analysis

Are Investors Undervaluing Humana (HUM) Right Now?

Zacks Investment Research · 4 Nov 2026neutral

Zacks Investment Research says its stock-picking focus is the Zacks Rank system, which emphasizes earnings estimates and estimate revisions, while also tracking value, growth, and momentum trends. The excerpt does not provide a specific assessment of Humana’s valuation.

Why it matters — HUM watchers should note the article’s stated analytical framework, but the excerpt offers no company-specific valuation conclusion.

Humana and athenahealth expand electronic prior authorization capabilities nationwide, reducing administrative burden for physicians and helping patients access care faster

Business Wire · 3 Nov 2026positive

Humana and athenahealth announced an expansion of electronic prior authorization capabilities across athenahealth’s nationwide network of more than 180,000 physicians and clinicians. The expanded process will be integrated into the tools clinicians already use.

Why it matters — The collaboration reflects Humana’s efforts to simplify prior authorization and support faster patient access to care.

Why Humana (HUM) Could Beat Earnings Estimates Again

Zacks Investment Research · 2 Nov 2026positive

Zacks Investment Research says Humana has a history of earnings surprises and currently has two key ingredients it views as supporting a likely beat in the next quarterly report.

Why it matters — The item highlights factors Zacks considers relevant to HUM’s upcoming quarterly earnings results.

Analysts Estimate Humana (HUM) to Report a Decline in Earnings: What to Look Out for

Zacks Investment Research · 30 Oct 2026negative

Zacks Investment Research says Humana does not have the combination of two key factors associated with a likely earnings beat in its upcoming report. The headline indicates analysts estimate a decline in earnings.

Why it matters — HUM watchers may note the expectations for the upcoming earnings report and the lack of factors supporting a likely earnings beat.

Humana Board Declares Payment of Quarterly Dividend to Stockholders

Business Wire · 29 Oct 2026neutral

Humana’s board declared a quarterly cash dividend of $0.885 per share, payable January 29, 2027, to stockholders of record at the close of business on December 24, 2026.

Why it matters — HUM watchers may note the dividend amount and the dates governing payment eligibility and distribution.

FAQ

Frequently asked questions about HUM stock

What is the HUM stock price forecast for 2026-2027?

The 26 Wall Street analysts covering Humana, Inc. have a median 12-month price target of $473, with estimates ranging from $280 to $596. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HUM stock a buy right now?

Of the 26 analysts covering Humana, Inc., 16 rate it a Buy, 9 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Humana, Inc. 51 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HUM?

As at 4 Nov 2026, Humana, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (90 of 100).

Will HUM stock go up?

No one can know that. What the data says: the median 12-month target from 26 analysts implies +13.3% from the last close, and Ticker Nerd's factor model ranks Humana, Inc. 51 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HUM stock forecast for 2030?

No analyst covering Humana, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HUM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $280 to $596 over the next 12 months.

How has HUM stock performed over the past year?

Humana, Inc. returned +50.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Humana, Inc. do?

Humana Inc. is a U.S.

What is the latest news on HUM?

The most recent item we track (Zacks Investment Research, 4 Nov 2026): "Are Investors Undervaluing Humana (HUM) Right Now?". Zacks Investment Research says its stock-picking focus is the Zacks Rank system, which emphasizes earnings estimates and estimate revisions, while also tracking value, growth, and momentum trends. The excerpt does not provide a specific assessment of Humana’s valuation.

Company

About Humana, Inc.

Humana Inc. is a U.S. healthcare company focused on health insurance and healthcare services. Humana provides a broad range of products and services through its Insurance and CenterWell segments, including Medicare Advantage plans, Medicare prescription drug coverage, Medicare supplement products, Medicaid-related offerings, military health administration, and employer-sponsored medical and specialty benefits. Through CenterWell, the company also delivers senior-focused primary care, pharmacy services, home health care, and other coordinated care solutions designed to support members across different stages of treatment. Humana serves individuals, families, employers, government program beneficiaries, and military personnel, with a strong emphasis on government-sponsored healthcare programs and senior care. Headquartered in Louisville, Kentucky, Humana plays a significant role in the U.S. managed care market by combining insurance coverage with integrated care delivery services.

CEO Mr. James A. Rechtin M.B.A. · 67,060 employees · United States · https://www.humana.com